ライフサイエンスコーパス: bone marrow failure

1 repair of these ICL can lead to leukemia and bone marrow failure.

2 e duplicated aluY repeat, thereby preventing bone marrow failure.

3 predisposition, developmental disorder, and bone marrow failure.

4 leading to their depletion and precipitating bone marrow failure.

5 yndrome that is characterized by progressive bone marrow failure.

6 uring autoimmune hemolytic anemia (AIHA) and bone marrow failure.

7 B and T cell lymphopenia, and progression to bone marrow failure.

8 DC patients usually die of bone marrow failure.

9 n and hematopoietic cell death, resulting in bone marrow failure.

10 f apoptosis and eventual symptoms related to bone marrow failure.

11 congenita, idiopathic pulmonary fibrosis and bone marrow failure.

12 ysplasia and thus serves as a model of human bone marrow failure.

13 sociated with both cancer predisposition and bone marrow failure.

14 rombasthenia, myelofibrosis, and progressive bone marrow failure.

15 y of hematopoietic stem cells as a cause for bone marrow failure.

16 es such as idiopathic pulmonary fibrosis and bone marrow failure.

17 uster, die prematurely because of congenital bone marrow failure.

18 onary fibrosis and successive generations by bone marrow failure.

19 l double-deficient mice rapidly precipitates bone marrow failure.

20 ity of combination therapy for patients with bone marrow failure.

21 eta overexpressing transgenic mouse model of bone marrow failure.

22 er associated with cancer predisposition and bone marrow failure.

23 aim to obtain therapeutic strategies against bone marrow failure.

24 s), leading to their rapid disappearance and bone marrow failure.

25 q- syndrome to a congenital syndrome causing bone marrow failure.

26 s and may represent genetic risk factors for bone marrow failure.

27 pneumonia but severe anemia due to complete bone marrow failure.

28 liferation and exhaustion and culminating in bone marrow failure.

29 in adult hematopoietic stem cells results in bone marrow failure.

30 e HSPC results in impaired hematopoiesis and bone marrow failure.

31 n of Gli1(+) cells abolished BMF and rescued bone marrow failure.

32 racranial hemorrhages), immunodeficiency and bone marrow failure.

33 , 3 (3%) an innate immune defect, and 2 (2%) bone marrow failure.

34 A) is an immune-mediated and serious form of bone marrow failure.

35 2 in regulation of p53 tumor suppression and bone marrow failure.

36 l mice have FA-like abnormalities, including bone marrow failure.

37 at FAN1 mutations cause chemosensitivity and bone marrow failure.

38 teoclast activity leads to osteopetrosis and bone marrow failure(1-9), whereas excess activity can co

39 enetic disorder characterized by progressive bone marrow failure, accelerated aging, and cancer predi

40 FA displays bone marrow failure, acute myeloid leukemia, and head an

41 ized by early-onset diabetes associated with bone marrow failure, affecting mostly the erythrocytic l

42 ction between progressing bone fragility and bone marrow failure after Pneumocystis lung infection in

43 es and IFN a/b receptor (IFrag(-/-)) develop bone marrow failure after Pneumocystis lung infection, w

44 p spontaneous hematologic sequelae including bone marrow failure, AML, MDS and complex random chromos

45 yndrome that is characterized by progressive bone marrow failure and a high risk of cancer.

46 is a disease of DNA repair characterized by bone marrow failure and a reduced ability to remove DNA

47 ssociation with developmental abnormalities, bone marrow failure and a strong predisposition to cance

48 ysplastic syndrome (MDS) is characterized by bone marrow failure and a strong propensity for leukemic

49 cts multiple systems and is characterized by bone marrow failure and a triad of abnormal skin pigment

50 nemia (FA) is characterized by a progressive bone marrow failure and an increased incidence of cancer

51 tures including mucocutaneous abnormalities, bone marrow failure and an increased predisposition to c

52 is a rare genetic disorder characterized by bone marrow failure and an increased risk for leukemia a

53 ized by hypoproliferative phenotypes such as bone marrow failure and anemia early in life, followed b

54 ups experienced early lethality due to acute bone marrow failure and aplastic anemia.

55 ide new tools for combinatorial therapies in bone marrow failure and bone marrow cancers.

56 chman-Diamond syndrome (SDS) is an inherited bone marrow failure and cancer predisposition syndrome t

57 se dyskeratosis congenita (DC), an inherited bone marrow failure and cancer predisposition syndrome.

58 enomic instability disorder characterized by bone marrow failure and cancer predisposition.

59 s, the mechanisms underlying the progressive bone marrow failure and cancer susceptibility of Fanconi

60 nconi anemia (FA) is a multigenic disease of bone marrow failure and cancer susceptibility stemming f

61 Fanconi anemia is a cancer-prone inherited bone marrow failure and cancer susceptibility syndrome w

62 zed by congenital malformations, progressive bone marrow failure and cancer susceptibility.

63 emia, a hereditary disorder characterized by bone marrow failure and cancer.

64 genome instability syndrome characterized by bone marrow failure and cellular hypersensitivity to DNA

65 erogeneous genetic disorder characterized by bone marrow failure and complex congenital anomalies.

66 ecessive disorder characterized by pediatric bone marrow failure and congenital anomalies.

67 with dyskeratosis congenita presenting with bone marrow failure and demonstrate that they are defici

68 acterized by congenital defects, progressive bone marrow failure and heightened cancer susceptibility

69 pe tends to have a relatively early onset of bone marrow failure and hematologic malignancies.

70 Bone marrow failure and hematopoietic damage is one of t

71 ed for patients with dyskeratosis congenita, bone marrow failure and idiopathic pulmonary fibrosis.

72 FA) is an inherited disease characterized by bone marrow failure and increased cancer risk.

73 a (FA) is a genetic disease characterized by bone marrow failure and increased cancer risk.

74 nd autosomal genetic disease associated with bone marrow failure and increased cancer, as well as sev

75 dult mice resulted in acute lethality due to bone marrow failure and intestinal atrophy featuring ste

76 mia (FA) is the most common genetic cause of bone marrow failure and is caused by inherited pathogeni

77 n Schwachman-Bodian-Diamond syndrome-a human bone marrow failure and leukaemia pre-disposition condit

78 Shwachman-Diamond syndrome, characterized by bone marrow failure and leukemia predisposition, is caus

79 h risk of developmental abnormalities, early bone marrow failure and leukemia.

80 mutated in hematologic malignancies such as bone marrow failure and leukemia.

81 e current concepts about "niche-facilitated" bone marrow failure and leukemic evolution, their underl

82 at spindle instability in SDS contributes to bone marrow failure and leukemogenesis.

83 We analyzed a patient with mild bone marrow failure and microcephaly who did not present

84 on demonstrate earlier-than-average onset of bone marrow failure and more severe congenital abnormali

85 ve been implicated in the pathophysiology of bone marrow failure and myelodysplastic syndromes (MDS).

86 chronic inflammation and the development of bone marrow failure and myeloproliferative neoplasms.

87 cing was performed in three index cases with bone marrow failure and neurological dysfunction and who

88 n, has reached adulthood without the typical bone marrow failure and paediatric cancers.

89 , characterized by a unique manifestation of bone marrow failure and pancytopenia among diseases caus

90 plasmacytic lymphoproliferative disorders to bone marrow failure and peripheral cytopenias, associate

91 using a previously uncharacterized inherited bone marrow failure and pre-leukemic syndrome.

92 This results in progressive bone marrow failure and predisposes to acute myeloid leu

93 ility, congenital malformations, progressive bone marrow failure and predisposition to hematologic ma

94 me (SDS) is a recessive disorder typified by bone marrow failure and predisposition to hematological

95 th a variety of developmental abnormalities, bone marrow failure and predisposition to leukemia and o

96 mia (FA), a genetic disorder associated with bone marrow failure and progression to leukemia and othe

97 We examined whether the cooccurrence of bone marrow failure and pulmonary fibrosis in the same i

98 diseases including various forms of cancer, bone marrow failure and pulmonary fibrosis.

99 disorder Fanconi anemia (FA) are progressive bone marrow failure and susceptibility to cancer.

100 ow that Trp53 is responsible for ICL-induced bone marrow failure and that loss of Trp53 is leukemogen

101 s characterized by congenital abnormalities, bone marrow failure, and cancer predisposition.

102 arious congenital abnormalities, progressive bone marrow failure, and cancer predisposition.

103 e characterized by congenital abnormalities, bone marrow failure, and cancer susceptibility.

104 e characterized by congenital abnormalities, bone marrow failure, and cancer susceptibility.

105 eases such as idiopathic pulmonary fibrosis, bone marrow failure, and cryptogenic liver cirrhosis.

106 y multiple congenital anomalies, progressive bone marrow failure, and high cancer risk.

107 e characterized by congenital abnormalities, bone marrow failure, and hypersensitivity to aldehydes a

108 r characterized by congenital abnormalities, bone marrow failure, and increased susceptibility to can

109 th Diamond-Blackfan anemia, a rare inherited bone marrow failure, and isolated congenital asplenia.

110 r characterized by congenital abnormalities, bone marrow failure, and marked cancer susceptibility.

111 r characterized by congenital abnormalities, bone marrow failure, and myeloid malignancies.

112 e characterized by congenital abnormalities, bone marrow failure, and susceptibility to leukemia and

113 ling in HSCs is found in two mouse models of bone marrow failure, and they show that treatment with r

114 sorder that manifests with hemolytic anemia, bone marrow failure, and thrombosis.

115 provide a mechanism for androgen therapy in bone marrow failure: androgens appear to regulate telome

116 Osteoporosis and bone marrow failure are additional unexplained complicat

117 Together, these data show that bone loss and bone marrow failure are partially linked, which suggests

118 mostly associated with inherited or acquired bone marrow failure, are believed to drive disease by sl

119 pendent of disease activity markers suggests bone marrow failure as a potential pathogenic factor in

120 disease, not only in myeloid cancers but in bone marrow failure as well.

121 of DC, including hyperpigmentation and fatal bone marrow failure at 4-5 mo of age.

122 eases, thrombohemorrhagic complications, and bone marrow failure because of myelofibrosis and leukemi

123 ns in the FANC genes and is characterized by bone marrow failure, birth defects, and a high incidence

124 oni anemia is a genetic disease resulting in bone marrow failure, birth defects, and cancer that is t

125 s congenita (DC) is a rare inherited form of bone marrow failure (BMF) caused by mutations in telomer

126 repair disorder characterized by progressive bone marrow failure (BMF) from hematopoietic stem and pr

127 Bone marrow failure (BMF) in Fanconi anemia (FA) patient

128 The mechanism of bone marrow failure (BMF) in paroxysmal nocturnal hemogl

129 Although acquired bone marrow failure (BMF) is considered a T cell-mediate

130 Although acquired bone marrow failure (BMF) is considered a T cell-mediate

131 An improved understanding of the bone marrow failure (BMF) mechanisms in Fanconi anemia (

132 A substantial number of individuals with bone marrow failure (BMF) present with one or more extra

133 Inherited bone marrow failure (BMF) syndromes are a heterogeneous

134 The inherited bone marrow failure (BMF) syndromes are a rare and diver

135 s with high-risk hematologic malignancies or bone marrow failure (BMF) who received haploidentical bo

136 alities, chromosome instability, progressive bone marrow failure (BMF), and a strong predisposition t

137 a is characterized by a mucocutaneous triad, bone marrow failure (BMF), and presence of short telomer

138 es in 2 siblings presenting with progressive bone marrow failure (BMF), immunodeficiency, and develop

139 have been associated with the development of bone marrow failure (BMF).

140 e thrombocytopenia progressing to trilineage bone marrow failure (BMF).

141 (FA) is the most frequent inherited cause of bone marrow failure (BMF).

142 associated with nail dystrophy, leucoplakia, bone marrow failure, cancer predisposition and other fea

143 Fanconi anemia (FA) is a genetic disease of bone marrow failure, cancer susceptibility, and sensitiv

144 characterized by hemolysis, thrombosis, and bone marrow failure caused by defective expression of gl

145 is a rare genetic disorder characterized by bone marrow failure, congenital abnormalities, and an in

146 is a rare genetic disorder that can lead to bone marrow failure, congenital abnormalities, and incre

147 These mice rapidly succumbed to fatal bone marrow failure, demonstrating that Srsf2-mutated ce

148 an explanation for its clinical activity in bone marrow failure, despite already elevated endogenous

149 in Fanconi anemia, which is characterized by bone marrow failure, developmental abnormalities, and a

150 Fanconi anemia (FA) patients exhibit bone marrow failure, developmental defects and cancer.

151 as, including haemolysis, sepsis and genetic bone marrow failure diseases such as Diamond-Blackfan an

152 Fanconi anemia (FA) is an inherited bone marrow failure disorder associated with a high inci

153 Diamond-Blackfan Anemia (DBA) is a bone marrow failure disorder characterized by low red bl

154 ditary breast and ovarian cancers as well as bone marrow failure disorder Fanconi anemia (FA).

155 nd recapitulates the salient features of the bone marrow failure disorder MDS.

156 aplastic anemia (SAA) is a life-threatening bone marrow failure disorder that can be treated with bo

157 mal nocturnal hemoglobinuria (PNH) is a rare bone marrow failure disorder that manifests with hemolyt

158 Fanconi anemia (FA) is a rare bone marrow failure disorder with defective DNA interstr

159 and Shwachman-Diamond syndrome, an inherited bone marrow failure disorder with high risk of developin

160 ance of detecting PNH cells in PNH and other bone marrow failure disorders are highlighted, and indic

161 PNH) are pathogenically related nonmalignant bone marrow failure disorders linked to T-cell-mediated

162 led to the idea that this and perhaps other bone marrow failure disorders result from an inadequate

163 s with DC as well as 244 patients with other bone marrow failure disorders.

164 etween patients with DC and those with other bone marrow failure disorders.

165 ults in depletion of germ cells and complete bone marrow failure due to increased apoptosis, culminat

166 ROR1 lysed tumors in mice but induced lethal bone marrow failure due to recognition of ROR1(+) stroma

167 ve defects and die prematurely from complete bone marrow failure due to the activation of an ATR-depe

168 ations in telomerase complex genes can cause bone marrow failure, dyskeratosis congenita, and acquire

169 utosomal recessive disorder characterized by bone marrow failure, exocrine pancreatic dysfunction, an

170 receptor (IFrag(-/-)) developed progressive bone marrow failure following infection, while lymphocyt

171 topoiesis in vivo in a novel murine model of bone marrow failure generated by constitutive hepatic ex

172 with LIG4 mutations, pancytopenia leading to bone marrow failure has not been observed.

173 By 2 weeks, in addition to bone marrow failure, he had evidence of alopecia and muc

174 (DC), an inherited syndrome characterized by bone marrow failure, hyperpigmentation, and nail dystrop

175 of isolated anemia, the pathogenesis of true bone marrow failure (i.e., low bone marrow cellularity a

176 and a broad range of pathologies, including bone marrow failure, immunodeficiency, and developmental

177 on, responsible for the primary induction of bone marrow failure in a subset of AA and MDS patients.

178 eper understanding of the molecular basis of bone marrow failure in FA and the cellular role of RAD51

179 ng DNA repair, the mechanisms underlying the bone marrow failure in FA patients are poorly defined.

180 ematopoiesis may underlie the progression to bone marrow failure in FA.

181 Therefore, the emergence of bone marrow failure in Fanconi anaemia is probably due t

182 ations for understanding the pathogenesis of bone marrow failure in Fanconi anemia and suggest possib

183 underlying molecular mechanisms that promote bone marrow failure in Fanconi anemia are incompletely u

184 ced by progressive stem cell loss leading to bone marrow failure in hereditary dyskeratosis congenita

185 at somatic deletion of Recql4 causes a rapid bone marrow failure in mice that involves cells from acr

186 synthesis in haematopoietic cells and caused bone marrow failure in mice.

187 al observations and laboratory evidence link bone marrow failure in myelodysplastic syndrome (MDS) to

188 lure followed by apoptosis may contribute to bone marrow failure in patients with FA.

189 opoietic cell transplantation (HCT) can cure bone marrow failure in patients with Fanconi anemia (FA)

190 ells is decreased, reflecting a component of bone marrow failure in PNH.

191 eptor signaling could only partially prevent bone marrow failure in response to Pneumocystis infectio

192 personal and research protocol experience of bone marrow failure in the Hematology Branch of the Nati

193 lead to telomere shortening and progressive bone marrow failure in the premature aging syndrome dysk

194 ed to rare human disorders that present with bone marrow failure including Fanconi anemia (FA).

195 n studies to produce some characteristics of bone marrow failure, including a proliferative advantage

196 dyskeratosis congenita (DC) characterized by bone marrow failure, intrauterine growth retardation, de

197 Progressive bone marrow failure is a major cause of morbidity and mo

198 Bone marrow failure is a nearly universal complication o

199 However, bone marrow failure is the primary pathological feature

200 ere variant of DC in which an early onset of bone marrow failure leading to combined immunodeficiency

201 cts in telomere maintenance and repair cause bone marrow failure, liver cirrhosis, and pulmonary fibr

202 te the molecular pathogenesis of spontaneous bone marrow failure, MDS and AML in FA.

203 sence of wildtype support cells succumbed to bone marrow failure (median survival, 328 days) characte

204 osomal instability syndrome characterized by bone marrow failure, myelodysplasia (MDS), and acute mye

205 lop hematologic complications such as severe bone marrow failure, myelodysplastic syndrome, or acute

206 , n = 32; beta-thalassemia major, n = 6; and bone marrow failure, n = 5) were analyzed: median age, 1

207 echanism might explain why birth defects and bone marrow failure occur in Fanconi anemia, and may hav

208 his phenomenon is demonstrated by congenital bone marrow failure occurring in DNA-PKcs(3A/3A) mutant

209 to the heightened cancer predisposition and bone marrow failure of individuals with mutated FA prote

210 baseline cytopenias and develop spontaneous bone marrow failure or diverse hematologic malignancies

211 haematopoiesis and immunity in patients with bone marrow failure or hematological malignancies.

212 be associated with hematopoietic exhaustion, bone marrow failure, or even oncogenic transformation.

213 of Tak1(-/-) HSPCs and partially repress the bone marrow failure phenotype of Tak1(-/-) mice.

214 estriction (IUGR) with gonadal, adrenal, and bone marrow failure, predisposition to infections, and h

215 infection accelerated osteoclastogenesis as bone marrow failure progressed.

216 Additionally, an arrest of bone marrow failure progression was observed in patients

217 or older with thrombocytopenia secondary to bone marrow failure, requiring prophylactic platelet tra

218 In addition, regenerative bone marrow failure resulting in pancytopenia is another

219 stem, which phenocopied the highly penetrant bone marrow failure seen in Fanconi anaemia patients.

220 increased apoptosis, thus recapitulating the bone marrow failure seen in MDS.

221 23B), reported in prior MDS/AML or inherited bone marrow failure series (DNAH9, NAPRT1 and SH2B3) or

222 ome (SDS) (OMIM #260400) is a rare inherited bone marrow failure syndrome (IBMFS) that is primarily c

223 ct disease categories: a classical inherited bone marrow failure syndrome and a 'ribosomopathy'.

224 eratosis congenita, DBA is both an inherited bone marrow failure syndrome and a cancer predisposition

225 be viewed as an overlap between a dysplastic bone marrow failure syndrome and an oligoblastic leukemi

226 Fanconi anemia (FA) is an inherited bone marrow failure syndrome associated with a progressi

227 wachman-Diamond syndrome (SDS), an inherited bone marrow failure syndrome associated with leukemia pr

228 ribosomal subunit maturation to an inherited bone marrow failure syndrome associated with leukemia pr

229 Dyskeratosis congenita, an inherited bone marrow failure syndrome associated with mucocutaneo

230 iamond Blackfan Anemia (DBA) is a congenital bone marrow failure syndrome associated with ribosomal g

231 to dyskeratosis congenita (DC), an inherited bone marrow failure syndrome caused by defects in telome

232 linked dyskeratosis congenita (DC) is a rare bone marrow failure syndrome caused by mostly missense m

233 amond Blackfan anaemia (DBA) is a congenital bone marrow failure syndrome characterised by selective

234 Dyskeratosis congenita (DC) is a multisystem bone marrow failure syndrome characterized by a triad of

235 Dyskeratosis congenita (DC) is a multisystem bone marrow failure syndrome characterized by a triad of

236 Diamond-Blackfan anemia (DBA), an inherited bone marrow failure syndrome characterized by anemia tha

237 Fanconi anemia (FA) is an inherited bone marrow failure syndrome characterized by chromosoma

238 Dyskeratosis congenita (DC) is an inherited bone marrow failure syndrome characterized by cutaneous

239 iamond Blackfan anemia (DBA) is an inherited bone marrow failure syndrome characterized by erythroid

240 iamond-Blackfan anemia (DBA) is a congenital bone marrow failure syndrome characterized by erythroid

241 TERT and hTR cause dyskeratosis congenita, a bone marrow failure syndrome characterized by mucocutane

242 iamond Blackfan anemia (DBA) is an inherited bone marrow failure syndrome characterized by red cell a

243 The progressive bone marrow failure syndrome dyskeratosis congenita (DC)

244 ka TCAB1), which is mutated in the inherited bone marrow failure syndrome dyskeratosis congenita, is

245 erase deficiency in the X-linked form of the bone marrow failure syndrome dyskeratosis congenita, mut

246 Dyskeratosis congenita (DC) is an inherited bone marrow failure syndrome in which the known suscepti

247 genes drive Diamond-Blackfan anemia (DBA), a bone marrow failure syndrome that can also predispose in

248 our data suggest that SCI causes an acquired bone marrow failure syndrome that may contribute to chro

249 congenital neutropenia (CN) is a preleukemic bone marrow failure syndrome with a 20% risk of evolving

250 In addition to being an inherited bone marrow failure syndrome, DBA is also categorized as

251 gy to create a mouse model for the inherited bone marrow failure syndrome, DBA.The result, while reca

252 ability, including the most common inherited bone marrow failure syndrome, Fanconi anaemia.

253 is congenita (DC), a heterogeneous inherited bone marrow failure syndrome, have abnormalities in telo

254 nd syndrome (SDS; OMIM 260400), an inherited bone marrow failure syndrome, is caused by mutations in

255 described and is a constitutional inherited bone marrow failure syndrome.

256 fan anemia (DBA) is a cancer-prone inherited bone marrow failure syndrome.

257 of Shwachman-Diamond syndrome, an inherited bone marrow failure syndrome.

258 keratosis congenita (DC) is a rare inherited bone marrow failure syndrome.

259 scovered that ERCC6L2 (which is mutated in a bone-marrow failure syndrome) codes for a canonical non-

260 vely, these observations identify a distinct bone-marrow-failure syndrome due to mutations in ERCC6L2

261 Diamond-Blackfan anemia (DBA), a congenital bone-marrow-failure syndrome, is characterized by red bl

262 PURPOSE OF REVIEW: Inherited bone marrow failure syndromes (IBMFS) are a diverse set

263 Inherited bone marrow failure syndromes (IBMFSs) are characterized

264 sm of clonal selection and leukemogenesis in bone marrow failure syndromes and our data suggest that

265 The inherited bone marrow failure syndromes are clinically distinct bu

266 Inherited bone marrow failure syndromes are human conditions in wh

267 Patients with inherited bone marrow failure syndromes are usually identified whe

268 Mutations in ribosomal proteins cause bone marrow failure syndromes associated with increased

269 nifestations of telomere disease include the bone marrow failure syndromes dyskeratosis congenita and

270 riptase, telomerase, are associated with the bone marrow failure syndromes dyskeratosis congenita, ap

271 Other bone marrow failure syndromes have been attributed to de

272 ng their contributions to the development of bone marrow failure syndromes in Tak1-knockout mice (Tak

273 addition of SDS to the growing list of human bone marrow failure syndromes involving the ribosome.

274 are, emerging data reveal that the inherited bone marrow failure syndromes may be underdiagnosed on t

275 emia at older age is complex and ranges from bone marrow failure syndromes to chronic kidney disease,

276 primary immune deficiencies, and congenital bone marrow failure syndromes with scores >=3 had increa

277 Androgens have been used in the treatment of bone marrow failure syndromes without a clear understand

278 of Treacher Collins syndrome, are inherited bone marrow failure syndromes, each of which has a marke

279 stic anemia, the paradigm of immune-mediated bone marrow failure syndromes, is characterized by hemat

280 Like most other bone marrow failure syndromes, it is associated with a m

281 needed to identify genes causally related to bone marrow failure syndromes, myelodysplastic syndromes

282 d to define the relationship between PNH and bone marrow failure syndromes.

283 s in the 5q-syndrome, DBA, and perhaps other bone marrow failure syndromes.

284 tor cell (HSPC) depletion in immune-mediated bone marrow failure syndromes.

285 rited and acquired red cell disorders and in bone marrow failure syndromes.

286 e development of hematologic malignancies or bone marrow failure syndromes.

287 lar causes have been recognized to result in bone marrow failure syndromes: (1) defects in the Fancon

288 -Hreidarsson syndrome (HHS), are multisystem bone-marrow-failure syndromes in which the principal pat

289 ngenita, a complex syndrome characterized by bone marrow failure, telomerase enzyme deficiency, and p

290 a (AA) and myelodysplasia (MDS) are forms of bone marrow failure that are often part of the same prog

291 gamma-irradiation, Parp-2-/- mice exhibited bone marrow failure that correlated with reduced long-te

292 e molecular details of FA, the origin of the bone marrow failure that is central to this condition fo

293 tations in telomere biology genes leading to bone-marrow failure, these data provide evidence that ge

294 Bone marrow failure was prevented by the reconstitution

295 unusual among primary immunodeficiencies and bone marrow failures, was due to a blockade in the bone

296 velop a Fanconi Anemia murine model to study bone marrow failure, we found that Fancd2(-/-) mice have

297 ly lethal, and deletion in adult mice led to bone marrow failure whereas parenchymal organs composed

298 Approximately 50% of patients with bone marrow failure who have clinical evidence of PNH at

299 Patients with bone marrow failure who have PNH cells detected by high-

300 , a rare congenital disease characterized by bone marrow failure with neutropenia, exocrine pancreati